Union Health Ministry Amends Drugs Rules, 1945 to Regulate Cell, Gene & Xenograft Therapies under CLAA
On 4 July 2026, the Union Health Ministry amended the Drugs Rules, 1945 to bring cell, stem‑cell, gene‑therapy and xenograft products under the CLAA licensing framework, aiming to curb unregulated clinics and create a clear regulatory pathway. The move has significant UPSC relevance for Polity (central‑state coordination) and Health (emerging biotechnologies) but challenges remain in infrastructure, workforce and approval timelines.
Overview The CLAA framework has been extended to cover cell and stem‑cell products, gene therapies and xenografts. The amendment, announced on 4 July 2026 , closes a regulatory gap that allowed many clinics to market unproven stem‑cell cures. While the change does not guarantee immediate approval or lower prices, manufacturers must still prove safety, quality and efficacy under the Drugs and Cosmetics Act . Key Developments Amendment revises Rules 75, 75A, 76 and 76A, and updates licensing forms (27D, 27DA, 28D, 28DA) to include advanced therapies. Both Central and State licensing authorities will jointly oversee manufacturing licences for these products. Regulatory coverage now includes regenerative treatments , CAR‑T cell therapy , gene‑replacement/editing products and animal‑tissue derived devices like heart valves. The move aims to curb unregulated clinics offering costly, unproven stem‑cell procedures for conditions like autism and spinal‑cord injury. Important Facts Until 2018, stem‑cell and cell‑based products were classified merely as “new drugs” without a dedicated licensing pathway. The amendment fills this void by providing a clear procedural route for manufacturers. Notable Indian advances include NexCAR19 by ImmunoACT, and ongoing CRISPR‑based gene‑editing projects such as CRISPR ‑based therapy BIRSA‑101 for sickle‑cell disease being developed by CSIR‑IGIB and the Serum Institute. UPSC Relevance Understanding this amendment is vital for GS2 (Polity) as it illustra
Quick Reference
Key Insight
New CLAA rules tighten control over stem‑cell, gene and xenograft therapies
Key Facts
- 4 July 2026 को घोषित संशोधन Drugs Rules, 1945 के Rules 75, 75A, 76 और 76A को बदलता है।
- Licensing forms 27D, 27DA, 28D और 28DA को उन्नत थेरेपीज़ को शामिल करने के लिए अपडेट किया गया है।
- CLAA (Centrally Licensed Approving Authority) अब cell‑based उत्पादों, gene therapies और xenografts को नियमन करता है।
- Both Central and State drug authorities will jointly issue manufacturing licences for these products.
- परिवर्तन का उद्देश्य महंगे, अनप्रूव्ड stem‑cell क्योर प्रदान करने वाले अनियमित क्लीनिकों को रोकना है।
- India’s first indigenous CAR‑T therapy, NexCAR19, 2023 में अनुमोदित हुई, जो biotech विकास को दर्शाती है।
- 2018 तक stem‑cell उत्पादों को “new drugs” माना जाता था और कोई समर्पित मार्ग नहीं था।
Background
Previously, cell and gene therapies fell through a regulatory gap, allowing dubious clinics to operate. The amendment aligns India’s drug law with global standards, reflecting central‑state cooperation (GS2) and the need to ensure safety of emerging health technologies (GS3).
UPSC Syllabus
- Prelims_GS — National Current Affairs
- Prelims_GS — Biology and Health
- GS2 — Government policies and interventions for development
Mains Angle
GS3 – Discuss how the amendment to the Drugs Rules, 1945 addresses regulatory challenges of advanced biologics and its impact on public health and innovation.